NZ714288A - Extended-release formulation for reducing the frequency of urination and method of use thereof - Google Patents
Extended-release formulation for reducing the frequency of urination and method of use thereofInfo
- Publication number
- NZ714288A NZ714288A NZ714288A NZ71428813A NZ714288A NZ 714288 A NZ714288 A NZ 714288A NZ 714288 A NZ714288 A NZ 714288A NZ 71428813 A NZ71428813 A NZ 71428813A NZ 714288 A NZ714288 A NZ 714288A
- Authority
- NZ
- New Zealand
- Prior art keywords
- urination
- frequency
- reducing
- extended
- release formulation
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- 238000013265 extended release Methods 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 230000027939 micturition Effects 0.000 title abstract 2
- 238000009472 formulation Methods 0.000 title 1
- 239000000730 antalgic agent Substances 0.000 abstract 1
- 239000003160 antidiuretic agent Substances 0.000 abstract 1
- 229940124538 antidiuretic agent Drugs 0.000 abstract 1
- 239000000812 cholinergic antagonist Substances 0.000 abstract 1
- 230000003111 delayed effect Effects 0.000 abstract 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 abstract 1
- 239000003149 muscarinic antagonist Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002048 spasmolytic effect Effects 0.000 abstract 1
- ZAFYATHCZYHLPB-UHFFFAOYSA-N zolpidem Chemical compound N1=C2C=CC(C)=CN2C(CC(=O)N(C)C)=C1C1=CC=C(C)C=C1 ZAFYATHCZYHLPB-UHFFFAOYSA-N 0.000 abstract 1
- 229960001475 zolpidem Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
- A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/06—Anti-spasmodics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Methods and pharmaceutical compositions for reducing the frequency of urination are disclosed. The composition may include zolpidem and one or more analgesic agents optionally further including an antimuscarinic agent, antidiuretic agent or spasmolytic. The composition may be formulated for immediate release, delayed release, extended release or combination thereof.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/424,000 US8236857B2 (en) | 2010-07-08 | 2012-03-19 | Extended-release formulation for reducing the frequency of urination and method of use thereof |
US13/487,348 US20120244221A1 (en) | 2010-07-08 | 2012-06-04 | Extended-release formulation for reducing the frequency of urination and method of use thereof |
NZ630471A NZ630471A (en) | 2012-03-19 | 2013-03-13 | Extended-release formulation for reducing the frequency of urination and method of use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
NZ714288A true NZ714288A (en) | 2016-12-23 |
Family
ID=49223209
Family Applications (6)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NZ630471A NZ630471A (en) | 2012-03-19 | 2013-03-13 | Extended-release formulation for reducing the frequency of urination and method of use thereof |
NZ718163A NZ718163A (en) | 2012-03-19 | 2013-03-13 | Extended-release formulation for reducing the frequency of urination and method of use thereof |
NZ712594A NZ712594A (en) | 2012-03-19 | 2013-03-13 | Extended-release formulation for reducing the frequency of urination and method of use thereof |
NZ714288A NZ714288A (en) | 2012-03-19 | 2013-03-13 | Extended-release formulation for reducing the frequency of urination and method of use thereof |
NZ628079A NZ628079A (en) | 2012-03-19 | 2013-03-14 | Extended-release formulation for reducing the frequency of urination and method of use thereof |
NZ714662A NZ714662A (en) | 2012-03-19 | 2013-03-14 | Extended-release formulation for reducing the frequency of urination and method of use thereof |
Family Applications Before (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NZ630471A NZ630471A (en) | 2012-03-19 | 2013-03-13 | Extended-release formulation for reducing the frequency of urination and method of use thereof |
NZ718163A NZ718163A (en) | 2012-03-19 | 2013-03-13 | Extended-release formulation for reducing the frequency of urination and method of use thereof |
NZ712594A NZ712594A (en) | 2012-03-19 | 2013-03-13 | Extended-release formulation for reducing the frequency of urination and method of use thereof |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NZ628079A NZ628079A (en) | 2012-03-19 | 2013-03-14 | Extended-release formulation for reducing the frequency of urination and method of use thereof |
NZ714662A NZ714662A (en) | 2012-03-19 | 2013-03-14 | Extended-release formulation for reducing the frequency of urination and method of use thereof |
Country Status (15)
Country | Link |
---|---|
EP (2) | EP2827852A4 (en) |
JP (5) | JP2015510928A (en) |
KR (4) | KR20140134333A (en) |
CN (4) | CN104302284A (en) |
AU (4) | AU2013235518B2 (en) |
BR (2) | BR112014020271A8 (en) |
CA (2) | CA2866853A1 (en) |
HK (3) | HK1251469A1 (en) |
MX (3) | MX2014011128A (en) |
MY (2) | MY174090A (en) |
NZ (6) | NZ630471A (en) |
RU (3) | RU2669565C2 (en) |
SG (2) | SG11201500408VA (en) |
WO (2) | WO2013142197A1 (en) |
ZA (2) | ZA201405862B (en) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10596127B2 (en) | 2013-03-14 | 2020-03-24 | Wellesley Pharmaceuticals, Llc | Composition for reducing the frequency of urination, method of making and use thereof |
DK3024474T3 (en) | 2013-07-23 | 2022-03-28 | Serenity Pharmaceuticals Llc | COMPOSITIONS INCLUDING DESMOPRESSINE IN COMBINATION WITH A BETA-3-ADRENOR RECEPTOR AGONIST |
AU2014396189A1 (en) * | 2014-06-06 | 2016-12-22 | Wellesley Pharmaceuticals, Llc | Pharmaceutical formulation for reducing frequency of urination and method of use thereof |
KR101809908B1 (en) * | 2014-07-21 | 2018-01-25 | 주식회사 종근당 | Pharmaceutical composition comprising 5-α reductase inhibitor |
CN106999538A (en) * | 2014-11-20 | 2017-08-01 | 阿勒根公司 | Method and composition comprising minirin Yu alpha-2 adrenoceptor antagonist-combination |
KR20180066113A (en) * | 2015-09-30 | 2018-06-18 | 웰즐리 파마슈티컬스 엘엘씨 | Composition for reducing urinary frequency |
EP3355864A4 (en) * | 2015-09-30 | 2019-05-22 | Wellesley Pharmaceuticals, LLC | Composition for reducing the frequency of urination, method of making and use thereof |
CN105238124B (en) * | 2015-11-16 | 2018-02-09 | 太仓东能环保设备有限公司 | A kind of antibacterial mastic powder |
JP6294924B2 (en) | 2016-09-05 | 2018-03-14 | 株式会社Subaru | Vehicle travel control device |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20010040819A (en) * | 1998-02-10 | 2001-05-15 | 가마꾸라 아끼오 | Preparations with controlled release |
US20020102309A1 (en) * | 1999-09-14 | 2002-08-01 | Jane C. I. Hirsh | Controlled release formulation for administration of an anti-inflammatory naphthalene derivative |
DE10116978A1 (en) * | 2001-04-05 | 2002-10-10 | Merck Patent Gmbh | Kappa opiate agonists for the treatment of diseases of the bladder |
US20030091630A1 (en) * | 2001-10-25 | 2003-05-15 | Jenny Louie-Helm | Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data |
EP1476146A1 (en) * | 2002-02-19 | 2004-11-17 | Pharmacia Corporation | Use of cyclooxygenase inhibitors and antimuscarinic agents for the treatment of incontinence |
BR0311414A (en) * | 2002-06-07 | 2005-03-15 | Yamanouchi Pharma Co Ltd | Therapeutic agent for an overactive bladder |
US20040054008A1 (en) * | 2002-09-13 | 2004-03-18 | Tohru Araki | Medicament for treatment of nocturia |
PL1492519T3 (en) * | 2003-03-21 | 2007-04-30 | Dynogen Pharmaceuticals Inc | Methods for treating lower urinary tract disorders using antimuscarinics and alpha-2-delta subunit calcium channel modulators |
CA2746531C (en) * | 2003-03-21 | 2016-06-28 | Mcneil-Ppc, Inc. | Non-steroidal anti-inflammatory drug dosage form |
EP1627876A1 (en) * | 2004-08-20 | 2006-02-22 | Ferring B.V. | Heterocyclic condensed compounds useful as antidiuretic agents |
JP5173190B2 (en) * | 2004-08-25 | 2013-03-27 | 武田薬品工業株式会社 | Preventive and therapeutic agent for stress urinary incontinence and screening method thereof |
MX2007016307A (en) * | 2005-06-17 | 2008-03-05 | Dynamis Therapeutics Inc | Treatment of inflammatory conditions. |
US20080085314A1 (en) * | 2005-07-29 | 2008-04-10 | Shalaby Shalaby W | Solid oral formulations for combination therapy |
PL1933833T3 (en) * | 2005-09-02 | 2011-09-30 | Theravida Inc | Therapy for the treatment of overactive bladder |
WO2010138441A1 (en) * | 2009-05-28 | 2010-12-02 | Aptapharma, Inc. | Multilayer oral tablets containing a non-steroidal anti-inflammatory drug and/or acetaminophen |
GB201003731D0 (en) * | 2010-03-05 | 2010-04-21 | Univ Strathclyde | Immediate/delayed drug delivery |
US20120244221A1 (en) * | 2010-07-08 | 2012-09-27 | Wellesley Pharmaceuticals, Llc | Extended-release formulation for reducing the frequency of urination and method of use thereof |
US20120010294A1 (en) * | 2010-07-08 | 2012-01-12 | Dill David A | Compositions and methods for the inhibition of muscle contraction |
-
2013
- 2013-03-13 AU AU2013235518A patent/AU2013235518B2/en not_active Ceased
- 2013-03-13 BR BR112014020271A patent/BR112014020271A8/en not_active Application Discontinuation
- 2013-03-13 NZ NZ630471A patent/NZ630471A/en not_active IP Right Cessation
- 2013-03-13 MY MYPI2014702434A patent/MY174090A/en unknown
- 2013-03-13 JP JP2015501754A patent/JP2015510928A/en active Pending
- 2013-03-13 NZ NZ718163A patent/NZ718163A/en not_active IP Right Cessation
- 2013-03-13 CN CN201380015062.3A patent/CN104302284A/en active Pending
- 2013-03-13 NZ NZ712594A patent/NZ712594A/en not_active IP Right Cessation
- 2013-03-13 WO PCT/US2013/030901 patent/WO2013142197A1/en active Application Filing
- 2013-03-13 MX MX2014011128A patent/MX2014011128A/en unknown
- 2013-03-13 EP EP13763764.1A patent/EP2827852A4/en not_active Withdrawn
- 2013-03-13 CN CN201710373440.5A patent/CN107157991A/en active Pending
- 2013-03-13 KR KR1020147029163A patent/KR20140134333A/en not_active Application Discontinuation
- 2013-03-13 CA CA2866853A patent/CA2866853A1/en not_active Abandoned
- 2013-03-13 NZ NZ714288A patent/NZ714288A/en not_active IP Right Cessation
- 2013-03-13 SG SG11201500408VA patent/SG11201500408VA/en unknown
- 2013-03-13 RU RU2014142025A patent/RU2669565C2/en not_active IP Right Cessation
- 2013-03-14 BR BR112014020113A patent/BR112014020113A8/en not_active Application Discontinuation
- 2013-03-14 CN CN201711086139.2A patent/CN107789626A/en active Pending
- 2013-03-14 EP EP13763665.0A patent/EP2827851A4/en not_active Withdrawn
- 2013-03-14 KR KR20147024604A patent/KR20140134284A/en active Search and Examination
- 2013-03-14 RU RU2014142066/15A patent/RU2599017C2/en not_active IP Right Cessation
- 2013-03-14 MX MX2014011129A patent/MX2014011129A/en unknown
- 2013-03-14 NZ NZ628079A patent/NZ628079A/en not_active IP Right Cessation
- 2013-03-14 CN CN201380015025.2A patent/CN104321056A/en active Pending
- 2013-03-14 AU AU2013235507A patent/AU2013235507B2/en not_active Ceased
- 2013-03-14 SG SG11201500409SA patent/SG11201500409SA/en unknown
- 2013-03-14 NZ NZ714662A patent/NZ714662A/en not_active IP Right Cessation
- 2013-03-14 KR KR1020177002422A patent/KR20170015537A/en active Application Filing
- 2013-03-14 WO PCT/US2013/031617 patent/WO2013142274A1/en active Application Filing
- 2013-03-14 MY MYPI2014702174A patent/MY175764A/en unknown
- 2013-03-14 CA CA2866755A patent/CA2866755A1/en not_active Abandoned
- 2013-03-14 JP JP2015501785A patent/JP2015510936A/en active Pending
- 2013-03-14 RU RU2016133305A patent/RU2016133305A/en not_active Application Discontinuation
- 2013-03-14 KR KR1020187038194A patent/KR20190003840A/en not_active Application Discontinuation
-
2014
- 2014-08-11 ZA ZA2014/05862A patent/ZA201405862B/en unknown
- 2014-08-21 ZA ZA2014/06146A patent/ZA201406146B/en unknown
- 2014-09-17 MX MX2019008817A patent/MX2019008817A/en unknown
-
2015
- 2015-05-27 HK HK18110965.0A patent/HK1251469A1/en unknown
- 2015-05-27 HK HK15105034.0A patent/HK1204553A1/en unknown
-
2016
- 2016-05-04 JP JP2016092868A patent/JP2016172752A/en active Pending
-
2017
- 2017-05-11 AU AU2017203139A patent/AU2017203139B2/en not_active Ceased
- 2017-05-15 AU AU2017203246A patent/AU2017203246B2/en not_active Ceased
- 2017-09-20 JP JP2017179685A patent/JP2018024693A/en active Pending
-
2018
- 2018-03-10 HK HK18103371.3A patent/HK1243921A1/en unknown
- 2018-05-15 JP JP2018093416A patent/JP2018138602A/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NZ714288A (en) | Extended-release formulation for reducing the frequency of urination and method of use thereof | |
MX2016001037A (en) | Inhibitors of transcription factors and uses thereof. | |
PH12016500024A1 (en) | Bromodomain inhibitor | |
IL236892B (en) | Combination of immunoconjugate and antibody for use in therapy, pharmaceutical composition and kit comprising same | |
DOP2014000031A (en) | 4- (8-METOXI-1 - ((1-METOXIPROPAN-2-IL) -2- (TETRAHIDRO-2H-PIRAN-4-IL) -1H-IMIDAZO [4,5-C] QUINOLIN-7-IL) -3,5-DIMETHYLISOXAZOL AND ITS USE AS A BROMODOMINIUM INHIBITOR | |
HK1220631A1 (en) | Anionic-core composition for delivery of therapeutic agents, and methods of making and using the same | |
NZ630805A (en) | Pharmaceutical combinations comprising a thionucleotide analog | |
MX366899B (en) | New compounds. | |
WO2012024620A3 (en) | Autotaxin inhibitors and uses thereof | |
EA033311B1 (en) | Benzoxaborole derivatives as antibacterial agents | |
MX349004B (en) | New compounds. | |
EP2617425A4 (en) | Pharmaceutical association for treating and/or preventing myoma and/or endometriosis, use of resveratrol and progestogen, pharmaceutical composition for treating and/or preventing myoma and/or endometriosis, medicament for treating and/or preventing myoma and/or endometriosis, kit and method for treating and/or preventing myoma and/or endometriosis | |
WO2015056094A3 (en) | Pharmaceutical composition comprising a trpa1 antagonist and an analgesic agent | |
MX2014008284A (en) | Delayed-release formulation for reducing the frequency of urination and method of use thereof. | |
PH12015501982A1 (en) | Pharmaceutical compositions comprising everolimus | |
MX2014008283A (en) | Extended-release formulation for reducing the frequency of urination and method of use thereof. | |
MX2015006223A (en) | Pharmaceutical compositions of cetp inhibitors. | |
GB201014391D0 (en) | Drug composition and its use in therapy | |
IN2014MN02269A (en) | ||
HK1197235A1 (en) | Dihydropyrazoles, pharmaceutical compositions thereof and their use for the treatment of fertility disorders | |
MY171526A (en) | Pharmaceutical formulation for reducing frequency of urination and method of use thereof | |
MX2016005092A (en) | Vaginal inserted estradiol pharmaceutical compositons and methods. | |
WO2011101634A3 (en) | Methods of prevention or treatment of triggered inflammatory reactions using tumor necrosis factor alpha antagonist | |
MX2016016039A (en) | Pharmaceutical formulation for reducing frequency of urination and method of use thereof. | |
TN2011000352A1 (en) | New combination of active ingredients containing a non steroidal anti inflammatory drug and a colchicoside derivative |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PSEA | Patent sealed | ||
RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 13 MAR 2020 BY GRIFFITH HACK Effective date: 20170328 |
|
RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 13 MAR 2021 BY CPA GLOBAL Effective date: 20200424 |
|
LAPS | Patent lapsed |